ライフサイエンスコーパス: monoclonal immunoglobulin

1 a ratio is used to determine the presence of monoclonal immunoglobulin.

2 enotypes characterized by over-production of monoclonal immunoglobulins.

3 esults in overproduction of large amounts of monoclonal immunoglobulins.

4 We used a human monoclonal immunoglobulin A (IgA) antibody (NAD) to type

5 2D6 is a dimeric monoclonal immunoglobulin A (IgA) specific for the nonre

6 We tested the ability of a human monoclonal immunoglobulin-A (IgA) antibody specific for

7 alence of MGUS and characterized patterns of monoclonal immunoglobulin abnormalities prior to MM diag

8 itrogen (BUN), supernatant IL-4, serum IL-6, monoclonal immunoglobulin and beta2-microglobulin, as we

9 erative disorder that produces a nephrotoxic monoclonal immunoglobulin and does not meet previously d

10 a (MM) is characterized by the production of monoclonal immunoglobulin and is associated with suppres

11 mu) N3 mice overexpressed Myc(His), produced monoclonal immunoglobulin, and exhibited a unique plasma

12 we present a proof of concept screening for monoclonal immunoglobulin as a leukemia tumor marker usi

13 e glomerulonephritis, C3 glomerulopathy, and monoclonal immunoglobulin-associated glomerulonephritis.

14 c lymphocytic leukemia (B-CLL) cells express monoclonal immunoglobulins carrying either kappa or lamb

15 Monoclonal immunoglobulin deposition disease (MIDD) is a

16 ndings and outcome in 34 patients with renal monoclonal immunoglobulin deposition disease (MIDD), whi

17 common entities are light chain amyloidosis, monoclonal immunoglobulin deposition disease and myeloma

18 ight chain amyloidosis (AL) are disorders of monoclonal immunoglobulin deposition in which normally s

19 Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is a distinc

20 Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is classifie

21 ant of proliferative glomerulonephritis with monoclonal immunoglobulin deposits excluded monoclonal d

22 that feature increased circulating levels of monoclonal immunoglobulin fragments that require metabol

23 myeloma, is usually related to deposition of monoclonal immunoglobulin free light chains (FLCs) and d

24 Monoclonal immunoglobulin free light chains (FLCs) are u

25 injury has been linked to an excess level of monoclonal immunoglobulin free light chains (FLCs) in th

26 s) are directly related to the production of monoclonal immunoglobulin free light chains (FLCs), whic

27 rder that can produce significant amounts of monoclonal immunoglobulin free light chains (FLCs).

28 Monoclonal immunoglobulin G (IgG) antibodies to CD44 (an

29 Although both polyclonal and monoclonal immunoglobulin G (IgG) inhibited secondary pr

30 and adapted interface for the attachment of monoclonal immunoglobulin G (IgGNS1) and to favor specif

31 dL monoclonal peak in the gamma region, with monoclonal immunoglobulin G and lambda light chain detec

32 Among 34 patients (91.9%) with monoclonal immunoglobulin G gammopathy, 20 (58.8%) had k

33 As a result, isotopic resolution of monoclonal immunoglobulin G was achieved, and we have es

34 ification and characterization of two murine monoclonal immunoglobulin G1 antibodies (MAbs), 1-F1 and

35 ab, formerly IMC-A12, is a recombinant human monoclonal immunoglobulin G1 antibody that targets insul

36 S315 is a fully human, monoclonal immunoglobulin G1 neutralizing antibody, spec

37 a high-affinity engineered human anti-PD-L1 monoclonal immunoglobulin-G1 antibody that inhibits the

38 AMG 157 is a human anti-TSLP monoclonal immunoglobulin G2lambda that binds human TSLP

39 -936558 (MDX-1106) - a fully human anti-PD-1 monoclonal immunoglobulin-G4 that blocks ligand binding

40 isoform of the light chain of a fully human monoclonal immunoglobulin gamma2 (IgG2) antibody panitum

41 Our studies reveal that different monoclonal immunoglobulin Gs (IgGs) and chimeric IgGs sh

42 eritubular amorphous deposits of a truncated monoclonal immunoglobulin heavy chain (HC) bearing a del

43 The monoclonal immunoglobulin heavy chains were also classif

44 disease remains unclear, but the role of the monoclonal immunoglobulin (Ig) light chain (LC) is stron

45 s is a protein misfolding disease in which a monoclonal immunoglobulin (Ig) light chain (LC) with a c

46 plasma cell dyscrasia in which the secreted monoclonal immunoglobulin (Ig) light chains form amyloid

47 The many binding studies of monoclonal immunoglobulin (Ig) produced by plasmacytomas

48 All cases showed monoclonal immunoglobulin (IG) rearrangement.

49 g as covalent and noncovalent homodimers, or monoclonal immunoglobulin (Ig) wherein the LC and heavy

50 asma cells produce excessive quantities of a monoclonal immunoglobulin (Ig), known as M-protein.

51 ith kidney disease through the production of monoclonal immunoglobulin (Ig).

52 ith kidney disease through the production of monoclonal immunoglobulin (Ig).

53 is study explored whether dupilumab, a human monoclonal immunoglobulin (Ig)G4 antibody that blocks th

54 ed with the overproduction of light-chain or monoclonal immunoglobulins (Igs).

55 ted and led to reduction in tumor-associated monoclonal immunoglobulin in 3 of 4 patients with measur

56 yloid fibrils composed of amyloid A protein, monoclonal immunoglobulin lambda light chain, Leu60Arg v

57 ular and peritubular amorphous deposits of a monoclonal immunoglobulin LC, leading to nodular glomeru

58 yretin (senile systemic amyloidosis, SSA) or monoclonal immunoglobulin light chain (AL amyloidosis).

59 Deposition of monoclonal immunoglobulin light chain (LC) aggregates in

60 Monoclonal immunoglobulin light chain (LC) crystalline i

61 The monoclonal immunoglobulin light chain FR2-CDR2-FR3 was s

62 s is correlated with the overproduction of a monoclonal immunoglobulin light chain protein by a B-lym

63 ng from systemic extracellular deposition of monoclonal immunoglobulin light chain variable domains i

64 (AL) results from overproduction of unstable monoclonal immunoglobulin light chains (LCs) and the dep

65 In multiple myeloma diseases, monoclonal immunoglobulin light chains (LCs) are abundan

66 in amyloidosis (AL), fibrillar deposition of monoclonal immunoglobulin light chains (LCs) in vital or

67 n incurable protein misfolding disease where monoclonal immunoglobulin light chains misfold and depos

68 is a protein conformation disorder in which monoclonal immunoglobulin light chains produced by clona

69 ell dyscrasia characterized by misfolding of monoclonal immunoglobulin light chains which leads to ag

70 e deposition of amyloid fibrils derived from monoclonal immunoglobulin light chains.

71 osition of fibrils in patients overproducing monoclonal immunoglobulin light chains.

72 idosis-including heart involvement of either monoclonal immunoglobulin light-chain (AL) or transthyre

73 of amyloid that can infiltrate the heart are monoclonal immunoglobulin light-chain amyloid and transt

74 acytic infiltration of the bone marrow and a monoclonal immunoglobulin M (IgM) protein.

75 (i.p.) administration of radiolabeled human monoclonal immunoglobulin M (IgM), which is reactive wit

76 clonal lymphoplasmacytic cells that produce monoclonal immunoglobulin M (IgM).

77 plasmacytic expansion accompanied by a serum monoclonal immunoglobulin M (IgM).

78 ation between VWF levels < 130 U/dL and both monoclonal immunoglobulin M concentration (mIgMC) and vi

79 the urine (>/=0.2 g/24 h), absence of intact monoclonal immunoglobulin (M protein) in the serum, and

80 -organ damage or symptoms, a small amount of monoclonal immunoglobulin (M protein), and low volume of

81 We sought to characterize monoclonal immunoglobulin (M-Ig) light chains before cli

82 , and IgM; examined sera for the presence of monoclonal immunoglobulins (M proteins); and looked for

83 ght chains (FLCs), soluble CD30 (sCD30), and monoclonal immunoglobulins (M-proteins).

84 Therapeutic monoclonal immunoglobulins (mAbs) are used to treat pati

85 posits were associated with a serum or urine monoclonal immunoglobulins matching the conventional imm

86 Monoclonal immunoglobulin (MIg) associated renal disease

87 glomerulopathy (C3G) emphasizes the role of monoclonal immunoglobulin (MIg) in the occurrence of ren

88 Monoclonal immunoglobulin (MIg)-associated renal disease

89 Histologic recurrence (deposition of monoclonal immunoglobulin) occurred in 18 of 20 recipien

90 checkpoint blockade, commonly delivered as a monoclonal immunoglobulin of a single defined isotype.

91 121 (20%) had a monoclonal immunoglobulin or abnormal circulating free l

92 rns exist, they are all distinguished by the monoclonal immunoglobulin (or component) deposits.

93 phropathy it might be due to the presence of monoclonal immunoglobulin; or it might result from tumou

94 g bone malignant plasma cell infiltration, a monoclonal immunoglobulin peak, immunoglobulin deposit i

95 direct or indirect kidney injury caused by a monoclonal immunoglobulin produced by a B-cell or plasma

96 rrow aspiration and may fail to identify all monoclonal immunoglobulins produced by the body, the pre

97 nce of a small B-cell clone, responsible for monoclonal immunoglobulin production.

98 ly described mass spectrometry method termed monoclonal immunoglobulin rapid accurate mass measuremen

99 The monoclonal immunoglobulin, secreted by myeloma plasma ce

100 In addition, circulating monoclonal immunoglobulins spanning the entire populatio

101 ionship between the mucin deposition and the monoclonal immunoglobulins that are seen in almost all p

102 he hallmark biomarker in blood or urine is a monoclonal immunoglobulin, the monoclonal protein.

103 The binding of four monoclonal immunoglobulins, two with specificity for bet

104 idates having increased globulins.However, a monoclonal immunoglobulin was identified in only 3% of a

105 The serum monoclonal immunoglobulin was IgG kappaappa in 86%.

106 The concentration of monoclonal immunoglobulin was less than 1.0 g per decili

107 ns, should also be performed to identify the monoclonal immunoglobulin, which helps to establish the

108 le-down MS/MS sequencing of endogenous human monoclonal immunoglobulins with polyclonal immunoglobuli